Pituitary macroadenoma secreting thyrotropin and growth hormone: Remission of bihormonal hypersecretion in response to lanreotide therapy

Pituitary

Volumn 4, Issue 4, 2001, Pages 265-269

  Shimon, Ilan ^a   Nass, Dvora ^a   Gross, David J ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Growth hormone; Lanreotide; Pituitary adenoma; TSH

Indexed keywords

ANGIOPEPTIN; ANTITHYROID AGENT; GROWTH HORMONE; LEVOTHYROXINE; LONG ACTING DRUG; OCTREOTIDE; PROPYLTHIOURACIL; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; THYROID HORMONE; THYROTROPIN;

ADULT; ALPHA CHAIN; CASE REPORT; DRUG EFFECT; DRUG RESPONSE; FEMALE; GOITER; HEMIANOPIA; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRIORITY JOURNAL; REMISSION; REVIEW; THYROID HORMONE BLOOD LEVEL; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL;

ADENOMA; ANTINEOPLASTIC AGENTS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; SOMATOSTATIN; THYROTROPIN;

EID: 0035470161     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020706732701     Document Type: Review

References (20)

1. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary adenomas. Endocr Rev 1996;17:610-638.
2. Lloyd RV, Cano M, Chandler WF, Barkan AL, Horvath E, Kovacs K. Human growth hormone and prolactin secreting pituitary adenomas analysed by in situ hybridization. Am J Pathol 1989;134:605-613.
3. Scheithauer BW, Horvath E, Kovacs K, Laws ER Jr, Randall RV, Ryan N. Plurihormonal pituitary adenomas. Semin Diag Pathol 1986;3:69-82.
4. Beck-Peccoz P, Piscitelli G, Amr S, Ballabio M, Bassetti M, Giannattasio G, Spada A, Nissim M, Weintraub BD, Faglia G. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: Evidence for secretion of TSH with increased bioactivity. J Clin Endocrinol Metab 1986;62:704-711.
5. Hirasawa R, Hashimoto K, Makino S, Suemaru S, Takao T, Ota Z, Hoshida Y, Yoshino T, Akagi T. Effect of a long-acting somatostatin analogue (SMS 201-995) on a growth hormone and thyroid stimulating hormone-producing pituitary tumor. Acta Med Okayama 1991;45:107-115.
6. Links TP, Monkelbaan JF, Dullaart RP, van Haeften TW. Growth hormone-, alpha-subunit and thyrotropin-cosecreting pituitary adenoma in familial setting of pituitary tumour. Acta Endocrinol (Copenh) 1993;129:516-518.
7. Ozawa Y, Kameya T, Kasuga A, Naritaka H, Kanda N, Maruyama H, Saruta T. A functional thyrotropin- and growth hormone-secreting pituitary adenoma with a ultrastructurally monomorphic feature: A case study. Endocr J 1998;45:211-219.
8. Skoric T, Korsic M, Zarkovic K, Plavsic V, Besenski N, Breskovac L, Giljevic Z, Paladino J. Clinical and morphological features of undifferentiated monomorphous GH/TSH-secreting pituitary adenoma. Eur J Endocrinol 1999;140:528-537.
9. Shimatsu A, Murabe H, Nakamura Y, Mizuta H, Ihara C, Nakao K. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma, secreting thyrotropin, growth hormone and prolactin. Endocr J 1999;46:159-165.
10. Sano T, Horiguchi H, Xu B, Li C, Hino A, Sakaki M, Kannuki S, Yamada S. Double pituitary adenomas: Six surgical cases. Pituitary 1999;1:243-250.
11. Le Roith. Insulin-like growth factors. N Engl J Med 1997;336:633-640.
12. Shimon I, Nass D, Hadani M. Acromegaly with normal growth hormone levels: Response to Sandostatin-LAR treatment. Pituitary 2000;4:289-294.
13. Lamberts SWJ. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988;9:417-436.
14. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 1987;317:12-17.
15. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-240.
16. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 1994;40:421-428.
17. Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000;85:1487-1491.
18. Baldelli R, Colao A, Razzore P, Jaffrain-Era M-L, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000;85:4099-4103.
19. Cozzi R, Barausse M, Sberna M, Lodrini A, Franzini A, Lasio G, Attanasio R. Lanreotide 60 mg, a longer-acting somatostatin analog: Tumor shrinkage and hormonal normalization in acromegaly. Pituitary 2000;3:231-238.
20. Shimon I, Taylor JE, Dong JZ, Bitonte RE, Kim S, Morgan B, Coy DH, Culler MD, Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures: Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone and prolactin regulation. J Clin Invest 1997;99:789-798.